Axel Kloppe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Axel Kloppe has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Bernd Lemke
Dept of Cardiology and Angiology, Klinikum Luedenscheid, Luedenscheid, Germany
3 shared publicationsDejan Mijic
Dept of Cardiology and Angiology, Klinikum Luedenscheid, Luedenscheid, Germany
3 shared publications- Heba Farouk
Cardiovascular Medicine Department, Faculty of Medicine, Cairo University
2 shared publications - Karim El-Chilali
Department of Cardiovascular and Pulmonary Medicine, Prosper Hospital, Recklinghausen, Germany
2 shared publications A. Mügge
1 shared publicationAlexander Lind
1 shared publication
Latest Publications
- Open Access
- 29 June 2026
- Published by Sociedade Brasileira de Cardiologia in ABC Imagem Cardiovascular
- Vol. 39 (2)
Visualização da Aorta Ascendente pela Ecocardiografia Transtorácica: Uma Vista Paraesternal Longitudinal Modificada Poderia Fornecer Imagem Adicional de um Segmento Aórtico Mais Longo?
Introdução A avaliação da aorta ascendente é um componente essencial da ecocardiografia transtorácica (ETT) padrão. Embora a visualização da raiz da aorta
- 29 June 2026
- Published by Sociedade Brasileira de Cardiologia in ABC Imagem Cardiovascular
- Vol. 39 (2)
Open AccessVisualização da Aorta Ascendente pela Ecocardiografia Transtorácica: Uma Vista Paraesternal Longitudinal Modificada Poderia Fornecer Imagem Adicional de um Segmento Aórtico Mais Longo?
Introdução A avaliação da aorta ascendente é um componente essencial da ecocardiografia transtorácica (ETT) padrão. Embora a visualização da raiz da aorta
- Open Access
- 29 June 2026
- Published by Sociedade Brasileira de Cardiologia in ABC Imagem Cardiovascular
- Vol. 39 (2)
Visualization of the Ascending Aorta by Transthoracic Echocardiography: Could a Modified Parasternal Long-Axis View Provide Additional Imaging of a Longer Aortic Segment?
Introduction Assessment of the ascending aorta is an essential component of standard transthoracic echocardiography (TTE). While visualization of the
- 29 June 2026
- Published by Sociedade Brasileira de Cardiologia in ABC Imagem Cardiovascular
- Vol. 39 (2)
Open AccessVisualization of the Ascending Aorta by Transthoracic Echocardiography: Could a Modified Parasternal Long-Axis View Provide Additional Imaging of a Longer Aortic Segment?
Introduction Assessment of the ascending aorta is an essential component of standard transthoracic echocardiography (TTE). While visualization of the
- 1 April 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 209, 291-295
Long-term survival with Cardiac Contractility Modulation in patients with NYHA II or III symptoms and normal QRS duration
- 1 April 2016
- Published by Elsevier in International Journal of Cardiology
- Vol. 209, 291-295
Long-term survival with Cardiac Contractility Modulation in patients with NYHA II or III symptoms and normal QRS duration
- Open Access
- 26 February 2016
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 23 (1) , 114-119
A randomized comparison of 5 versus 12 hours per day of cardiac contractility modulation treatment for heart failure patients: A preliminary report
Cardiac contractility modulation (CCM) signals are non-excitatory electrical signals delivered during the absolute refractory period intended to improve contraction and cardiac function. Clinical trials have shown that CCM treatment significantly improves exercise tolerance and quality of life in symptomatic heart failure patients. Studies with CCM therapy typically include CCM delivery for 3, 5 or 7 h per day, although other configurations are also commonly used. Each has been associated with improved outcomes in heart failure, but it is not clear whether different application durations are associated with the various degrees of benefit. The purpose of the current pilot evaluation study was to evaluate the quality of life, exercise tolerance, and cardiac function, over a 6-month period when CCM was delivered for 5 h/day vs. 12 h/day. Increasing the daily CCM therapy duration is safe and as good as the standard CCM periods of application per day. This single center pilot evaluation study involved 19 medically refractory symptomatic patients with heart failure and reduced left ventricular function who underwent implantation of an Optimizer™ system (Impulse Dynamics, Orangeburg, NY, USA). Patients were randomized into one of two treatment groups; 5 h/day CCM treatment or 12 h/day CCM treatment. Subjects and evaluating physicians were blinded to the study group. Subjects returned to the hospital after 12 and 24 weeks. Efficacy evaluations included changes from baseline to 24 weeks in Minnesota Living With Heart Failure Questionnaire score (MLWHFQ), maximal oxygen consumption in the cardio-pulmonary stress test (peak VO2), New York Heart Association classification (NYHA), 6-min walk distance (6MWD), and ejection fraction (EF). At the end of 24 weeks, clinical improvement was observed in the entire cohort in all efficacy measures (mean change from baseline of -17.1 in MLWHFQ, -0.86 in NYHA, and improvement trend of 1.48 mL O2/kg/min in peak VO2, 31.3 m in 6MWD, and 2.25% in EF). There were no significant differences, either clinically or statistically, between the groups receiving CCM for 5 h/day vs. 12 h/day. Three subjects were voluntarily withdrawn before completing the study. One subject died from pneumonia after 125 days, and 6 serious adverse events were reported, none of which was classified as related to either the device or the procedure. Together with previously reported experience with CCM, delivery of CCM therapy is equally safe and appears similarly effective over the range of shorter (5 h) to longer (12 h) daily periods of application. Given the small sample size, further studies are warranted.
- 26 February 2016
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 23 (1) , 114-119
Open AccessA randomized comparison of 5 versus 12 hours per day of cardiac contractility modulation treatment for heart failure patients: A preliminary report
Cardiac contractility modulation (CCM) signals are non-excitatory electrical signals delivered during the absolute refractory period intended to improve contraction and cardiac function. Clinical trials have shown that CCM treatment significantly improves exercise tolerance and quality of life in symptomatic heart failure patients. Studies with CCM therapy typically include CCM delivery for 3, 5 or 7 h per day, although other configurations are also commonly used. Each has been associated with improved outcomes in heart failure, but it is not clear whether different application durations are associated with the various degrees of benefit. The purpose of the current pilot evaluation study was to evaluate the quality of life, exercise tolerance, and cardiac function, over a 6-month period when CCM was delivered for 5 h/day vs. 12 h/day. Increasing the daily CCM therapy duration is safe and as good as the standard CCM periods of application per day. This single center pilot evaluation study involved 19 medically refractory symptomatic patients with heart failure and reduced left ventricular function who underwent implantation of an Optimizer™ system (Impulse Dynamics, Orangeburg, NY, USA). Patients were randomized into one of two treatment groups; 5 h/day CCM treatment or 12 h/day CCM treatment. Subjects and evaluating physicians were blinded to the study group. Subjects returned to the hospital after 12 and 24 weeks. Efficacy evaluations included changes from baseline to 24 weeks in Minnesota Living With Heart Failure Questionnaire score (MLWHFQ), maximal oxygen consumption in the cardio-pulmonary stress test (peak VO2), New York Heart Association classification (NYHA), 6-min walk distance (6MWD), and ejection fraction (EF). At the end of 24 weeks, clinical improvement was observed in the entire cohort in all efficacy measures (mean change from baseline of -17.1 in MLWHFQ, -0.86 in NYHA, and improvement trend of 1.48 mL O2/kg/min in peak VO2, 31.3 m in 6MWD, and 2.25% in EF). There were no significant differences, either clinically or statistically, between the groups receiving CCM for 5 h/day vs. 12 h/day. Three subjects were voluntarily withdrawn before completing the study. One subject died from pneumonia after 125 days, and 6 serious adverse events were reported, none of which was classified as related to either the device or the procedure. Together with previously reported experience with CCM, delivery of CCM therapy is equally safe and appears similarly effective over the range of shorter (5 h) to longer (12 h) daily periods of application. Given the small sample size, further studies are warranted.
- 1 September 2014
- Vol. 23 (5) , 537-44
B-type natriuretic peptide is a strong independent predictor of long-term outcome after transcatheter aortic valve implantation.
The aim of this prospective study was to determine the impact of plasma B-type natriuretic peptide (BNP) on long-term outcome in patients undergoing transcatheter aortic valve implantation (TAVI). TAVI was performed either transfemorally or transaxillary using either the CoreValve prosthesis or Edwards SAPIEN prosthesis in 226 patients with symptomatic severe aortic valve stenosis and at high surgical risk. The examinations included measurements of plasma BNP and echocardiography before and at 30 days after TAVI. The primary study end-point was death from any cause after TAVI; the secondary end-point was defined as cardiovascular death. During a mean follow up of 728 ± 549 days, 72 patients died; 52 deaths were cardiovascular-related. Those patients who died had higher preprocedural plasma BNP levels compared to those who survived (1,305 ± 1,238 pg/ml versus 716 ± 954 pg/ml; p < 0.001). Plasma BNP was the strongest independent predictor of all-cause mortality (BNP > 475 pg/ml, hazard risk [HR] 3.049; 95% confidence interval [CI] 1.804-5.151; p < 0.001) and cardiovascular mortality (BNP > 475 pg/ml, HR 3.479; 95% CI 1.817-6.662; p < 0.001). In surviving patients, plasma BNP levels were decreased by 30 days after TAVI (pre-TAVI 874 ± 1,122 pg/ml; post TAVI 471 ± 569 pg/ml; p < 0.001). A plasma BNP level > 328 pg/ml at 30 days postoperatively was also associated with all-cause mortality (HR 8.125; 95% CI 3.097-21.318; p < 0.001). In patients undergoing TAVI, plasma BNP is the strongest independent predictor of all-cause mortality and cardiovascular mortality. Plasma BNP levels at 30 days after TAVI may provide prognostic information that should, potentially, lead to a more intensive therapy of these patients.
- 1 September 2014
- Vol. 23 (5) , 537-44
B-type natriuretic peptide is a strong independent predictor of long-term outcome after transcatheter aortic valve implantation.
The aim of this prospective study was to determine the impact of plasma B-type natriuretic peptide (BNP) on long-term outcome in patients undergoing transcatheter aortic valve implantation (TAVI). TAVI was performed either transfemorally or transaxillary using either the CoreValve prosthesis or Edwards SAPIEN prosthesis in 226 patients with symptomatic severe aortic valve stenosis and at high surgical risk. The examinations included measurements of plasma BNP and echocardiography before and at 30 days after TAVI. The primary study end-point was death from any cause after TAVI; the secondary end-point was defined as cardiovascular death. During a mean follow up of 728 ± 549 days, 72 patients died; 52 deaths were cardiovascular-related. Those patients who died had higher preprocedural plasma BNP levels compared to those who survived (1,305 ± 1,238 pg/ml versus 716 ± 954 pg/ml; p < 0.001). Plasma BNP was the strongest independent predictor of all-cause mortality (BNP > 475 pg/ml, hazard risk [HR] 3.049; 95% confidence interval [CI] 1.804-5.151; p < 0.001) and cardiovascular mortality (BNP > 475 pg/ml, HR 3.479; 95% CI 1.817-6.662; p < 0.001). In surviving patients, plasma BNP levels were decreased by 30 days after TAVI (pre-TAVI 874 ± 1,122 pg/ml; post TAVI 471 ± 569 pg/ml; p < 0.001). A plasma BNP level > 328 pg/ml at 30 days postoperatively was also associated with all-cause mortality (HR 8.125; 95% CI 3.097-21.318; p < 0.001). In patients undergoing TAVI, plasma BNP is the strongest independent predictor of all-cause mortality and cardiovascular mortality. Plasma BNP levels at 30 days after TAVI may provide prognostic information that should, potentially, lead to a more intensive therapy of these patients.
- 1 January 2011
- Published by Wiley in Journal of Arrhythmia
- Vol. 27 (Supplement) , OP68_5
Acute Myocardial Ischemia Detection with a New ST Segment Monitoring Algorithm in an ICD
- 1 January 2011
- Published by Wiley in Journal of Arrhythmia
- Vol. 27 (Supplement) , OP68_5
Acute Myocardial Ischemia Detection with a New ST Segment Monitoring Algorithm in an ICD
- Open Access
- 1 June 2005
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 7 (Supplement) , 139
614 Electrode implantation technique for biventricular pacemaker and ICD. Effective and safe access via the cephalic vein for all three leads
A. Kloppe, M. Neise, T. Fortmann, D. Fllgraf, D. Boppert, B. Lemke; 614 Electrode implantation technique for biventricular pacemaker and ICD. Effective and saf
- 1 June 2005
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 7 (Supplement) , 139
Open Access614 Electrode implantation technique for biventricular pacemaker and ICD. Effective and safe access via the cephalic vein for all three leads
A. Kloppe, M. Neise, T. Fortmann, D. Fllgraf, D. Boppert, B. Lemke; 614 Electrode implantation technique for biventricular pacemaker and ICD. Effective and saf
- 11 September 2004
- Published by IOP Publishing in Medical Engineering & Physics
- Vol. 26 (8) , 687-694
Mechanical and optical characteristics of a new fiber optical system used for cardiac contraction measurement
In order to obtain a better physiological performance and a closer restoration of the regular rhythm of failing hearts, a new fiber optical sensor system for the measurement of cardiac contraction has been developed. It consists of an opto-electrical unit and a sensing fiber which has to be positioned in the heart. The objective of this new fiber optic sensor system is to use the inotropic information to adjust a stimulation algorithm in single or multichamber pacing or to detect arrhythmia in insufficient heart function. In this study, the mechanical and optical characteristics of different fibers are investigated. The relationship between the attenuation (with an achieved numerical maximum of 0.3 dB), the bending diameter and the angle of bending is determined in a range of 20-160 mm. The most suitable fiber for the application in cardiological problems is determined (WT8 fiber), for which the sensitivity is analyzed. Additionally, power spectra are calculated from WT8 fiber signals obtained from pig hearts, working under physiological conditions. The maximal frequency response was 23 Hz. It is concluded that the fiber optical measurement of cardiac contraction is not only feasible and reproducible, but the WT8 fiber also shows optimal behavior in the range of parameters occurring in the heart chambers. Nevertheless, in order to restrict the measured signal reliably to bending processes within the chambers only, it is concluded that a special combined fiber has to be constructed with a high sensitivity only at its terminal section within the heart.
- 11 September 2004
- Published by IOP Publishing in Medical Engineering & Physics
- Vol. 26 (8) , 687-694
Mechanical and optical characteristics of a new fiber optical system used for cardiac contraction measurement
In order to obtain a better physiological performance and a closer restoration of the regular rhythm of failing hearts, a new fiber optical sensor system for the measurement of cardiac contraction has been developed. It consists of an opto-electrical unit and a sensing fiber which has to be positioned in the heart. The objective of this new fiber optic sensor system is to use the inotropic information to adjust a stimulation algorithm in single or multichamber pacing or to detect arrhythmia in insufficient heart function. In this study, the mechanical and optical characteristics of different fibers are investigated. The relationship between the attenuation (with an achieved numerical maximum of 0.3 dB), the bending diameter and the angle of bending is determined in a range of 20-160 mm. The most suitable fiber for the application in cardiological problems is determined (WT8 fiber), for which the sensitivity is analyzed. Additionally, power spectra are calculated from WT8 fiber signals obtained from pig hearts, working under physiological conditions. The maximal frequency response was 23 Hz. It is concluded that the fiber optical measurement of cardiac contraction is not only feasible and reproducible, but the WT8 fiber also shows optimal behavior in the range of parameters occurring in the heart chambers. Nevertheless, in order to restrict the measured signal reliably to bending processes within the chambers only, it is concluded that a special combined fiber has to be constructed with a high sensitivity only at its terminal section within the heart.